The most-cited Articles on
Recurrent Glioma


Home > Publications > The most-cited articles on > Recurrent glioma


Contents




Bibliometrics


*

Chen W, Lei C, Liu P, Liu Y, Guo X, Kong Z, Wang Y, Dai C, Wang Y, Ma W, Wang Y.
Progress and Prospects of Recurrent Glioma: A Recent Scientometric Analysis of the Web of Science in 2019.
World Neurosurg. 2019 Oct 19. 2020;134:e387-e399. doi: 10.1016/j.wneu.2019.10.078. PMID: 31639500. Bibliometric analysis.



The top 10 most-cited articles




Etiopathogenesis


*

Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJM, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF.
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Science. 2013 Dec 12. 2014;343(6167):189-193. doi: 10.1126/science.1239947. PMID: 24336570. Laboratory investigation.



Treatment


*

Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC.
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Lancet. 1995 Apr 22;345(8956):1008-12. doi: 10.1016/s0140-6736(95)90755-6. PMID: 7723496. Prospective study.



*

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
J Clin Oncol. 2009 Aug 31;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. PMID: 19720927. Phase 2 trial.



*

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA.
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
J Clin Oncol. 2008 Dec 29. 2009;27(5):740-5. doi: 10.1200/JCO.2008.16.3055. PMID: 19114704. Phase 2 trial.



*

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38. PMID: 18316689. Retrospective analysis.



*

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
J Clin Oncol. 2007 Oct 20;25(30):4722-9. doi: 10.1200/JCO.2007.12.2440. PMID: 17947719. Phase 2 trial.



*

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS.
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clin Cancer Res. 2007 Feb 15;13(4):1253-9. doi: 10.1158/1078-0432.CCR-06-2309. PMID: 17317837. Phase 2 trial.



*

Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK.
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
J Clin Oncol. 1999 Aug 1;17(8):2572-8. doi: 10.1200/JCO.1999.17.8.2572. PMID: 10561324. Phase 2 trial.



*

Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA.
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Br J Cancer. 2000 Aug 8;83(5):588-93. doi: 10.1054/bjoc.2000.1316. PMID: 10944597. Phase 2 trial.



*

Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA.
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
J Clin Oncol. 1999 Sep 1;17(9):2762-71. doi: 10.1200/JCO.1999.17.9.2762. PMID: 10561351. Phase 2 trial.
Erratum in: J Clin Oncol 1999 Nov 1;17(11):3693. doi: 10.1200/JCO.1999.17.11.3693. Correction.